SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 clinical trial results for their Duchenne Muscular Dystrophy treatment, potentially reversing a previous FDA rejection. The stock is currently halted, but the community is celebrating the news and anticipating a significant short squeeze, while also discussing buyout possibilities and criticizing those who doubted the company.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to a report of lowered AI sales quotas, sparking community debate about the company's AI strategy and its impact on the broader market. Some believe this indicates slowing customer adoption of Microsoft's AI products, while others see it as a temporary setback or even a manipulation tactic. The conversation also includes opinions on competition from Google's Gemini and the overall strength of Microsoft in the AI infrastructure landscape.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss its recent price movements and potential involvement in acquiring Warner Bros. Discovery assets. Community members are weighing the potential impact of a WBD deal, as well as recent reports of Netflix lobbying for regulatory approval, with some suggesting that the stock is being manipulated.

$SMOL is the first memecoin with a verified OnlyFans launched on Solana via pump.fun. It follows Smol, a rescued Alabama dachshund who survived hoarding, shelter hunger, and a 5-day post-spay escape before finding her forever home. Now pampered with treats and spa days, she shares wholesome content—no adult themes, just derpy faces, snack videos, and rescue love. $SMOL aims to normalize kindness and support animal welfare through the creator economy.

Smol Fans

$SMOL is gaining traction as a community-owned project, with supporters highlighting its unique narrative and potential for significant growth. The community is rallying around the project's mission, while drawing comparisons to established memecoins like $DOGE and focusing on its potential impact within the crypto space.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential implications of Marvell's acquisition of Celestial AI, a key POET customer, and the validation it provides for POET's photonic interposer technology. The community is speculating about increased demand for POET's products and potential acquisition by a larger player like Marvell or Broadcom, with some emphasizing the company's unique technology and strong cash position. Concerns remain around dilution and the company's ability to scale production.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a surge in data center demand, a Q3 earnings beat, and forward guidance exceeding expectations. The acquisition of Celestial AI for its interconnect technology is also fueling excitement, with the community discussing the strategic implications of vertical integration and potential synergies. However, some investors are wary of a potential overvaluation and are closely watching for a pullback.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors discuss its recent government contract win for autonomous border protection using drones, though some express disappointment as the stock dipped despite the positive news. The community debates whether the contract's value is already priced in, while others emphasize the long-term potential of ONDS as a key player in the growing autonomous systems and drone defense sector. Discussions also include speculation about future acquisitions and potential benefits from .16T implementation.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GTLB is trending amidst speculation of a potential acquisition by Datadog, reportedly considering a bid over $60 per share. While some investors are excited about a possible buyout, others express skepticism, citing past false rumors and questioning the long-term value. Community members are actively discussing the legitimacy of the reports and debating potential price targets.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike ($CRWD) is trending as analysts raise price targets following a strong quarter, highlighting the company's re-accelerating ARR and successful Flex licensing model. Community members are actively discussing the potential for further gains and whether to "buy the dip", while some express concerns about the stock's valuation. Bullish sentiment surrounds CrowdStrike's position in the cybersecurity sector, particularly regarding AI-driven solutions.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta (OKTA) is trending after Q3 earnings, with mixed sentiment as the company beat expectations but some investors are concerned by a lack of forward guidance. The community is actively discussing analyst ratings, price targets, and whether the stock is currently undervalued. Some traders are also considering short-term options strategies amidst the volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum purchased 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The stock was purchased...

Penny Stocks To Follow Now - November 12th

Leap Therapeutics, Bitfarms, MSP Recovery, Strive, Salarius Pharmaceuticals, HIVE Digital Technologies, and Beyond Meat are the seven Penny stocks to watch today, according to MarketBeat's stock...

Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement. read more...

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering PR Newswire HOUSTON, Nov...

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our...

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today's pre-market trading following fourth-quarter results.
read more...

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
read more...

12 titoli sanitari in movimento, after-market del 22/03/2024

Titoli in rialzo
Le azioni di Salarius Pharmaceuticals (NASDAQ:SLRX) sono cresciute del 33,90% a 0,83 dollari durante la sessione after-market di venerd .
Il titolo Masimo (NASDAQ:MASI) ha osservato...

12 acciones de salud en movimiento en la subasta de cierre del 22/03/2024

Acciones al alza
Salarius Pharmaceuticals (NASDAQ:SLRX) experimentaron un repunte del 35,29% para establecerse en los 0,84 d lares durante la sesi n del after-market del viernes.
Masimo (NASDAQ:MASI...

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Current Price	$0.83
Prev Close	$0.8554
Open	$0.8712
Dividend Yield	0.00%
50-Day Moving Average	$2.94
Beta	0.07
Avg. Volume	5.39M
PE Ratio	-0.02

52-Week High	$108.00
52-Week Low	$0.7106
Market Capitalization	$5.01M
EPS (Annual)	-$86.92
Price to Book	0.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc